Adalimumab in ulcerative colitis: ready for prime time.
1Humanitas Clinical and Research Center, Via Manzoni 56, 20089 Rozzano, Milan, Italy. sdanese@hotmail.com
Adalimumab is a new treatment for ulcerative colitis, offering effective relief for moderate-to-severe cases. This anti-tumour necrosis factor α therapy provides a valuable option for patients with inflammatory bowel disease seeking better quality of life.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease impacting quality of life.
- Current UC treatments lack efficacy or tolerability for many patients.
- Tumour necrosis factor α (TNF-α) is a key target for UC therapies.
Purpose of the Study:
- To review the evidence for adalimumab in treating ulcerative colitis.
- To assess adalimumab's efficacy and tolerability in UC patients.
Main Methods:
- Review of current clinical evidence and studies on adalimumab for UC.
- Analysis of treatment outcomes in moderate-to-severe ulcerative colitis patients.
Main Results:
- Adalimumab demonstrates compelling efficacy in moderate-to-severe ulcerative colitis.
- Adalimumab offers a new therapeutic option for UC management.
Conclusions:
- Adalimumab is an effective treatment for ulcerative colitis.
- Adalimumab provides a much-needed option for patients with inadequate treatment response.
More Related Videos
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
06:57Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease II: Ulcerative Colitis
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease III: Crohn's Disease
